NeuroPace Inc is a medical technology company that specializes in developing innovative neuromodulation devices aimed at transforming the treatment of neurological disorders. The company's flagship product is an implantable brain device that delivers responsive neurostimulation to manage epilepsy, helping patients who do not achieve adequate control with traditional medication. By continuously monitoring brain activity, NeuroPace's technology can provide targeted therapy in real-time, resulting in improved quality of life for individuals suffering from chronic seizures. Committed to advancing research and patient care, NeuroPace is at the forefront of personalized medicine in the neurological field. Read More
NEW YORK, June 02, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of NeuroPace, Inc. (“NeuroPace” or the “Company”) (NASDAQ: NPCE). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
NEW YORK, May 28, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of NeuroPace, Inc. (“NeuroPace” or the “Company”) (NASDAQ: NPCE). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
Wondering how the US markets performed in the middle of the day on Tuesday? Discover the movers and shakers of today's session in our comprehensive analysis.
MOUNTAIN VIEW, Calif., April 08, 2025 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today announced three-year effectiveness data from the Post-Approval Study (PAS) of the RNS® System, which showed an 82% median reduction in seizures in adults treated with brain-responsive stimulation for drug-resistant focal epilepsy (DRE).1 The data were presented in an oral presentation at the American Academy of Neurology (AAN) Annual Meeting, taking place in San Diego from April 5-9, 2025.
